| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/10731199.2012.712042 |
| P953 | full work available at URL | http://www.tandfonline.com/doi/pdf/10.3109/10731199.2012.712042 |
| P698 | PubMed publication ID | 22889326 |
| P2093 | author name string | Wen Li | |
| Xiangdong Gao | |||
| Yue Tong | |||
| Wenbing Yao | |||
| Mingming Gao | |||
| P2860 | cites work | Increasing the homogeneity, stability and activity of human serum albumin and interferon-alpha2b fusion protein by linker engineering | Q47653735 |
| The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study | Q51381364 | ||
| Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. | Q51565136 | ||
| Biological activity of GLP-1-analogues with N-terminal modifications | Q74665094 | ||
| Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability | Q79283090 | ||
| Production and purification of an analog of glucagon-like peptide-1 by auto-induction and on-column cleavage in Escherichia coli | Q115771126 | ||
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 | ||
| PEGylation, successful approach to drug delivery | Q28278538 | ||
| The Physiology of Glucagon-like Peptide 1 | Q28373115 | ||
| Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats | Q28578709 | ||
| Biology of incretins: GLP-1 and GIP | Q29617302 | ||
| Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome | Q29619211 | ||
| Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides | Q34128861 | ||
| A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. | Q34343581 | ||
| Multiple low-dose streptozotocin-induced diabetes in the mouse. Evidence for stimulation of a cytotoxic cellular immune response against an insulin-producing beta cell line | Q34613096 | ||
| Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes | Q36129110 | ||
| Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature | Q37728075 | ||
| The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice | Q38363214 | ||
| Prevalence of diabetes among men and women in China | Q39605920 | ||
| Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity | Q40681900 | ||
| Expression, purification, and C-terminal site-specific PEGylation of cysteine-mutated glucagon-like peptide-1. | Q43281505 | ||
| Intein-mediated expression and purification of an analog of glucagon-like peptide-1 in Escherichia coli | Q45326844 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 159-164 | |
| P577 | publication date | 2012-08-14 | |
| P1433 | published in | Artificial cells, nanomedicine, and biotechnology | Q27724536 |
| P1476 | title | Improving the anti-diabetic activity of GLP-1 by fusion with globular adiponectin | |
| P478 | volume | 41 |
Search more.